{"disease":{"id":"unresectable-cholangiocarcinoma","name":"unresectable cholangiocarcinoma"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cholangiocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"infigratinib","indication_name":"Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Truseltiq","generic_name":"INFIGRATINIB","company_name":"Helsinn Hlthcare","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03768414","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":452,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT03656536","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":167,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04801160","title":"REMS Combined With TAI for Unresectable HC","phase":"NA","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT04068194","title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03201458","title":"Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03942328","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06302621","title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05564403","title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01718327","title":"A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"GERCOR - Multidisciplinary Oncology Cooperative Group","has_results":false},{"nct_id":"NCT06501625","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03250273","title":"A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT04175912","title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04378023","title":"Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.","phase":"","overall_status":"RECRUITING","enrollment_count":34,"lead_sponsor_name":"Hospital Vall d'Hebron","has_results":false},{"nct_id":"NCT00286013","title":"Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT05738057","title":"Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":22,"lead_sponsor_name":"Hua Li","has_results":false},{"nct_id":"NCT06058663","title":"Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04088188","title":"Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT04301778","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT04251715","title":"mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT02994251","title":"A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Yale University","has_results":true}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}